Abstract
Neuroblastoma is a fatal childhood cancer, but lack of knowledge about the underlying causative genes has hampered the development of effective therapies. The identification of anaplastic lymphoma kinase (ALK) mutations as drivers of neuroblastoma has indicated that targeted therapy with ALK inhibitors might be a valuable strategy in the fight against this lethal cancer.
MeSH terms
-
Anaplastic Lymphoma Kinase
-
Humans
-
Neuroblastoma / drug therapy
-
Neuroblastoma / enzymology*
-
Neuroblastoma / pathology
-
Protein Kinase Inhibitors / therapeutic use*
-
Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Protein-Tyrosine Kinases / genetics
-
Receptor Protein-Tyrosine Kinases
Substances
-
Protein Kinase Inhibitors
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
Protein-Tyrosine Kinases
-
Receptor Protein-Tyrosine Kinases